Syntex (u.s.a.) Inc.

Other

Axys Pharmaceuticals, Inc.

Roche Diagnostics Operations, Inc.

Aventis Pharmaceuticals Inc.

Telik, Inc.

Roche Diagnostics Gmbh

Virobay, Inc.

F. Hoffmann-la Roche Ag

John W Patterson

Ronald Charles Hawley

David John Morgans, Jr

David Bernard Smith

Eric Brian Sjogren

Peter H Nelson

Robert James Weikert

Todd Richard Elworthy

David Garrett Loughhead

Alicia Cervantes

Teresa Lara

Dean R Artis

Ann M Waltos

Alejandra Trejo

Fidencio Franco

Mario Fernandez

John O Link

Salvatore Joseph Salamone

Mitali Ghoshal

Erasmus Huber

Eva Hoess

Allan R Dorn

Francisco X Talamas

Michael Graupe

Gerald F Sigler

Raymond Hui

Bruce H Devens

Ronald Patterson

Mario Fern Andez

Francisco X Talam As

Sheila M Zipfel

John C Rohloff

Jiayao Li

David John Aldous

Sukanthini Thurairatnam

Andreas Paul Timm

Lawrence M Kauvar

Jurg R Pfister

Frank Halley

Oliver L Saunders

Robert T Lum

Hugo O Villar

James T Palmer

Soon Hyung Woo

Wayne R Spevak

Dorit Ron

Valeri Martichonok

Stephen Dennis Pickett

Clifford M Bryant

Nicki Vasquez

Anna Voronova

Raynor Sturgis

Arnold J Martelli

Sophia Park

Barry A Bunin

Erica A Kraynack

Gene Napolitano

Fancisco X Talamas

Lawrence Wilhelm

Hugh Walborn

Justine Lai Yeun Quai

Raymond A Hui

Erasmus J Huber

Allan Dorn

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Amidino compounds as cysteine protease inhibitors

The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.

Conjugates of mycophenolic acid

A collar () is placed around the neck of a user () and is rested on the user's shoulders () with forward end portions () of said collar () resting on an upper part of a user's chest. Riser arms (orand) extend from front end portions (or) of the collar () to a video viewer () that is positioned in front of the user's eyes. The riser arms may extend substantially straight upwardly from the front end portions () of the collar (). Or, a lower portion () of each arm may extend upwardly and rearwardly from the end portions (or) to about the level of the user's ears, and then an upper portion may extend forwardly and upwardly from that level to the video viewer (). The collar () and riser () portions of the unit are foldable into a compact configuration for stowage.

Shoulder mounted device with eye-confronting portion forwardly of a user's eyes

The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

Compounds and compositions as cathepsin inhibitors

The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

Conjugates of uncompetitive inhibitors of inosine monophosphate dehydrogenase

The present invention relates to novel alkanoyl-substituted heterocyclic derivatives which are cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.

Compounds and compositions as protease inhibitors

Enzyme inhibition immunoassay

Compounds and compositions as cathepsin S inhibitors

Substituted stilbenes as glucose uptake enhancers

The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

A personal audio/visual device comprising a pair of normally spaced modules having lower contoured surfaces shaped to contact and be supported by the shoulders of a wearer. The two modules are coupled together at a back end thereof by a telescoping or folding structure adapted to allow horizontal adjustment between the modules. Integrated within each module are recessed audio speakers positionable adjacent the ears. In a preferred embodiment, the audio/visual device includes two pairs of submodules, each pair being coupled together by a hinge for pivoting movement within the same plane or scissoring movement in parallel planes. In an unfolded position, the lower submodules of the pairs rests on the shoulders of a wearer while the upper submodules touches the sides of a person's head and against the ears. In a folded position, the submodules are pivoted together and the telescoping or folding structure collapsed to minimize the space necessary to store the device.

Personal audio/video entertainment system

Compounds having immunomodulating activity are identified using a methodology which employs TER14687, TER10311 and/or TER17210 as standards. The effect candidate compounds have on PKC-theta interaction with cognate binding proteins is measured and compared with the standards. The interaction can be measured by a variety of techniques, including assessing translocation of said PKC-theta or fragment. Kits containing the TER14687, TER10311 and/or TER17210 standards are disclosed. TER14687, TER10311 and/or TER17210 are useful in modulating the immune system in a subject by reducing T-cell activity. TER14687, TER10311, TER17210 are used as leads to develop other compounds having immunomodulating activity.

Methods to identify immunomodulators using cognate interaction of

A radiographic film mask includes a planar sheet sized for receipt on an illuminated radiographic film examination box. The mask has two opaque sections and a transparent section. The transparent section is disposed on the sheet between the two opaque sections to form a radiographic film viewing area which has an area less than the entire area of the sheet. The sheet may include semi-transparent sections which border the viewing area and interconnect the opaque portions to provide reduced transmission of light along the marginal edges of the radiographic film.

Mask for viewing reduced-size radiographic film, particularly

Growing community of inventors

Mountain View, CA, United States of America

John W Patterson